Page 15 - reflections_dyslipidaemia_newsletter9_Final

REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #9 2025

RISK ASSESSMENT, PREVENTION, AND TREATMENT Dyslipidaemia

7. ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease. Morze J, et al. Eur Heart J. 2025
Apr 28:ehaf207. doi: 10.1093/eurheartj/ehaf207. Online ahead of print.

8. LDL-cholesterol, lipoprotein(a) and high-sensitivity low-density lipoprotein cholesterol, lipoprotein(a) and high-
sensitivity C-reactive protein are independent predictors of cardiovascular events. Markus MRP, et al. Eur Heart J.
2025 May 5:ehaf281. doi: 10.1093/eurheartj/ehaf281. Online ahead of print.

9. Lipoprotein(a) cardiovascular risk explained by LDL cholesterol, non-HDL cholesterol, ApoB, or hsCRP is minimal.
Thomas PE, et al. J Am Coll Cardiol. 2025 Jun 3;85(21):2046-2051.

10. Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary
prevention: The EPIC-Norfolk study. Kraaijenhof JM, et al. Eur Heart J. 2025 Apr 1:ehaf209. doi: 10.1093/eurheartj/
ehaf209. Online ahead of print.

11. Quantifying triglyceride-rich lipoprotein atherogenicity, associations with inflammation, and implications for risk
assessment using non-HDL cholesterol. Bjornson E, et al. J Am Coll Cardiol. 2024 Oct 1;84(14):1328-1338.
12. Safety and efficacy of moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy in
patients with atherosclerotic cardiovascular disease: A meta-analysis. Kelly FA, et al. J Clin Lipidol. 2024 Nov-
Dec;18(6):e893-e904.
SPECIAL POPULATIONS

13. Ages at coronary heart disease and death in familial hypercholesterolaemia: A Danish nationwide study spanning
44 years. Reeh J, et al. Eur Heart J. 2025 Mar 24;46(12):1144-1155.

14. Lipid metabolism in women: A review. van Oortmerssen JAE, et al. Atherosclerosis. 2025 Jun:405:119213.

Abbreviations
ACC, American College of Cardiology; AGS, American Geriatrics Society; AHA, American Heart Association; ANGPTL, angiopoietin-
like protein; apoB, apolipoproteinB; ApoCIII, apolipoprotein C-III; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass
index; CAC, coronary artery calcium; CHD, coronary heart disease; CI, confidence interval; CKD, chronic kidney disease; CLEAR,
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients; CT, computed tomography; CVD, cardiovascular
disease; DM, diabetes mellitus; EAS, European Atherosclerosis Society; EU, European Union; EWTOPIA 75, Ezetimibe Lipid-
Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older; FCS, familial chylomicronemia syndrome;
FGF, fibroblast growth factor; FLI, fatty liver index; GLP-1, glucagon-like peptide 1; HbA1c, glycated haemoglobin; HDL-C, high-
density lipoprotein cholesterol; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HOMA-IR, homeostasis model
assessment of insulin resistance; HR, hazard ratio; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; LLT,
lipid-lowering therapy; Lp(a), lipoprotein(a); LPL, lipoprotein lipase; MACE, major adverse cardiovascular event; MASH, metabolic-
associated steatohepatitis; MCS, multifactorial chylomicronemia syndrome; MESA, Multi-Ethnic Study of Atherosclerosis; MI,
myocardial infarction; NLA, National Lipid Association; NNT, number needed to treat; NRI, net reclassification improvement; PCE,
pooled cohort equation; PCSK9, proprotein convertase subtilisin/kexin type 9; PREVENT, Predicting Risk of Cardiovascular Disease
Events; PREVENTABLE, PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr adults; PRS, polygenic risk
scores; RCT, randomised controlled trial; SAMS, statin-associated muscle symptoms; SGLT2, sodium-glucose co-transporter 2;
siRNA, small interfering RNA; SITE, Statins in the Elderly; SMD, systemic metabolic disorder; STAREE, Statin Therapy for Reducing
Events in the Elderly; STREAM, Statins in Multimorbid Older Adults Without Cardiovascular Disease; SWEDEHEART, Swedish
Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended
Therapies; T2DM, type 2 diabetes mellitus; TRL, triglyceride-rich lipoproteins; UKB, UK Biobank.

TABLE OF CONTENTS